[EN] NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QU'INHIBITEURS DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
申请人:GLAXOSMITHKLINE LLC
公开号:WO2012162129A1
公开(公告)日:2012-11-29
This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.
这项发明涉及一种新型化合物,它们是酰辅酶A:二酰基甘油酰基转移酶1(DGAT-1)的抑制剂,以及含有它们的药物组合物,它们的制备方法,以及它们在治疗中的应用,用于预防或治疗与DGAT-1功能障碍相关的疾病,或者调节DGAT-1活性可能具有治疗益处的疾病,包括但不限于肥胖,与肥胖相关的疾病,高三酰甘油血症,高脂蛋白血症,乳糜微粒血症,脂质代谢异常,非酒精性脂肪肝炎,糖尿病,胰岛素抵抗,代谢综合征,丙型肝炎病毒感染,痤疮或其他皮肤疾病。